IBI3016
Phase 2Small molecule
Innovent Biologics (Suzhou) Co. Ltd.IBI3016 is one of 8 small molecule programs targeting Hypertensive. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Hypertensive
#DrugCompanyPhaseTrials
1Normodyne
AAlvogen Korea
Approved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ultomiris
AstraZenecaPhase 2
IBI3016
Innovent Biologics (Suzhou) Co. Ltd.Phase 2
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Standard Medical Therapy
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Calcium Channel Blocker
MMinia University
Preclinical
Antihypertensive Medication
UUniversity of Alberta
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IBI3016. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details